Treventis Corporation presents research from its anti-oligomer therapeutic program at AAIC

July 22, 2016 – Toronto, ON – Treventis Corporation presented research from its anti-oligomer therapeutic program at the Alzheimer’s Association International Conference in Toronto, showcasing the advances it is making in profiling (in vitro and in vivo) compounds that affect the earliest phases of beta-amyloid and tau oligomerization and demonstrating this unique mechanism of action using experimental techniques.

Mark Reed, Senior VP of Research at TREVENTIS, presented a poster entitled “Discovery of small molecule dual inhibitors of both beta-amyloid and tau oligomerization”, on behalf of the TREVENTIS therapeutics division.  This poster summarized the progress made towards in vitro and in vivo profiling […] Read more